Biotheus, a Chinese biotech firm focusing on the treatment of malignant tumours and autoimmune diseases, has secured over $100 million in its fourth funding round co-led by growth equity investor General Atlantic and Beijing-based investment firm IDG Capital.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
